Human-growth hormone injection-related Creutzfeldt-Jakob Disease (Q92020): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed label, description and/or aliases in pt-br, en |
||
| description / pt-br | description / pt-br | ||
A doença de Creutzfeldt-Jakob (DCJ) relacionada ao hormônio de crescimento humano é a DCJ em pacientes tratados com hormônio de crescimento humano derivado das hipófises do cérebro de doadores cadáveres. As características clínicas incluem ataxia cerebelar progressiva e um curso mais longo da doença do que na DCJe clássica. Após a proibição do uso de cadáveres para extração de hormônio do crescimento, a ocorrência de DCJ nessa forma foi drasticamente reduzida. | |||
| description / en | description / en | ||
Human growth hormone-related Creutzfeldt-Jakob Disease (CJD) is CJD in patients treated with human growth hormone derived from the pituitary glands in the brains of cadaveric donors. The clinical features include progressive cerebellar ataxia and a longer disease course than classical sCJD. After the prohibition of the cadaveric use for growth hormone, the occurrence of CJD in this manner has been drastically reduced. | |||
Revision as of 07:10, 16 August 2026
Human growth hormone-related Creutzfeldt-Jakob Disease (CJD) is CJD in patients treated with human growth hormone derived from the pituitary glands in the brains of cadaveric donors. The clinical features include progressive cerebellar ataxia and a longer disease course than classical sCJD. After the prohibition of the cadaveric use for growth hormone, the occurrence of CJD in this manner has been drastically reduced.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_866329807 |
||
| English | Human-growth hormone injection-related Creutzfeldt-Jakob Disease |
Human growth hormone-related Creutzfeldt-Jakob Disease (CJD) is CJD in patients treated with human growth hormone derived from the pituitary glands in the brains of cadaveric donors. The clinical features include progressive cerebellar ataxia and a longer disease course than classical sCJD. After the prohibition of the cadaveric use for growth hormone, the occurrence of CJD in this manner has been drastically reduced. |
